Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2012

Open Access 01-12-2012 | Research

The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays

Authors: Kambiz Sotoudeh, Forough Hashemi, Zahra Madjd, Alireza Sadeghipour, Saadat Molanaei, Elham Kalantary

Published in: Diagnostic Pathology | Issue 1/2012

Login to get access

Abstract

Background

c-MET is an oncogene protein that plays important role in gastric carcinogenesis and has been introduced as a prognostic marker and potential therapeutic target. The aim of this study was to evaluate the frequency of c-MET overexpression and its relationship with clinicopathological variables in gastric cancer of Iranian population using tissue microarray.

Methods

In a cross sectional study, representative paraffin blocks of 130 patients with gastric carcinoma treated by curative gastrectomy during a 2 years period of 2008–2009 in two university hospitals in Tehran-Iran were collected in tissue microarray and c-MET expression was studied by immunohistochemical staining.

Results

Finally 124 cases were evaluated, constituted of 99 male and 25 female with the average age of 61.5 years. In 71% (88/124) of tumors, c-MET high expression was found. c-MET high expression was more associated with intestinal than diffuse tumor type (P = 0.04), deeper tumor invasion, pT3 and pT4 versus pT1 and pT2 (P = 0.014), neural invasion (P = 0.002) and advanced TNM staging, stage 3 and 4 versus stage 1 and2 (P = 0.044). The c-MET high expression was not associated with age, sex, tumor location, differentiation grade and distant metastasis, but relative associations with lymph node metastasis (P = 0.065) and vascular invasion (P = 0.078) were observed.

Conclusions

c-MET oncogene protein was frequently overexpressed in Iranian gastric carcinomas and it was related to clinicopathological characteristics such as tumor type, depth of invasion, neural invasion and TNM staging. It can also support the idea that c-MET is a potential marker for target therapy in Iranian gastric cancer.

Virtual slides

The virtual slide(s) for this article can be found here: http://​www.​diagnosticpathol​ogy.​diagnomx.​eu/​vs/​9744598757151429​
Appendix
Available only for authorised users
Literature
1.
Brenner H, Rothenbacher D, Arndt V: Epidemiology of stomach cancer. Methods Mol Biol. 2009, 472: 467-477.CrossRefPubMed
2.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90.CrossRefPubMed
3.
Malekzadeh R, Derakhshan MH, Malekzadeh Z: Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med. 2009, 12: 576-583.PubMed
4.
Movahedi M, Afsharfard A, Moradi A, Nasermoaddeli A, Khoshnevis J, Fattahi F, Akbari ME: Survival rate of gastric cancer in Iran. J Res Med Sci. 2009, 14: 367-373.PubMedCentralPubMed
5.
Mousavi SM, Somi MH: Gastric cancer in Iran 1966–2006. Asian Pac J Cancer Prev. 2009, 10: 407-412.PubMed
6.
Hundahl SA, Phillips JL, Menck HR: The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer. 2000, 88: 921-932.CrossRefPubMed
7.
8.
Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E: Gastric cancer. Crit Rev Oncol Hematol. 2009, 71: 127-164.CrossRefPubMed
9.
Anderson C, Nijagal A, Kim J: Molecular markers for gastric adenocarcinoma: an update. Mol Diagn Ther. 2006, 10: 345-352.CrossRefPubMed
10.
Tahara E: Genetic alterations in human gastrointestinal cancers. The application to molecular diagnosis. Cancer. 1995, 75: 1410-1417.CrossRefPubMed
11.
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003, 4: 915-925.CrossRefPubMed
12.
Prat M, Narsimhan RP, Crepaldi T, Nicotra MR, Natali PG, Comoglio PM: The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer. 1991, 49: 323-328.CrossRefPubMed
13.
Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, Valente G, Giordano S, Cortesina G, Comoglio PM: Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene. 2000, 19: 1547-1555.CrossRefPubMed
14.
Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, Kim BJ, Bae JH, Hong YK, Lee KS, et al.: Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 1999, 59: 307-310.PubMed
15.
Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, et al.: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997, 16: 68-73.CrossRefPubMed
16.
Christensen JG, Burrows J, Salgia R: c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005, 225: 1-26.CrossRefPubMed
17.
Amemiya H, Kono K, Itakura J, Tang RF, Takahashi A, An FQ, Kamei S, Iizuka H, Fujii H, Matsumoto Y: c-Met expression in gastric cancer with liver metastasis. Oncology. 2002, 63: 286-296.CrossRefPubMed
18.
Li Y, Chen CQ, He YL, Cai SR, Yang DJ, He WL, Xu JB, Zan WH: Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol. 2012, [Epub ahead of print]
19.
Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H: The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer. 1999, 85: 1894-1902.CrossRefPubMed
20.
Retterspitz MF, Monig SP, Schreckenberg S, Schneider PM, Holscher AH, Dienes HP, Baldus SE: Expression of {beta}-catenin, MUC1 and c-met in diffuse-type gastric carcinomas: correlations with tumour progression and prognosis. Anticancer Res. 2010, 30: 4635-4641.PubMed
21.
Tang Z, Zhao M, Ji J, Yang G, Hu F, He J, Shen H, Gao Z, Zhao A, Li J, Lu Y: Overexpression of gastrin and c-met protein involved in human gastric carcinomas and intestinal metaplasia. Oncol Rep. 2004, 11: 333-339.PubMed
22.
Taniguchi K, Yonemura Y, Nojima N, Hirono Y, Fushida S, Fujimura T, Miwa K, Endo Y, Yamamoto H, Watanabe H: The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer. 1998, 82: 2112-2122.CrossRefPubMed
23.
Tsugawa K, Yonemura Y, Hirono Y, Fushida S, Kaji M, Miwa K, Miyazaki I, Yamamoto H: Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology. 1998, 55: 475-481.CrossRefPubMed
24.
Wang J, Lu Y, Li J: The overexpression of c-met oncogene correlation with gastric mucosal lesion. Zhonghua Yi Xue Za Zhi. 1996, 76: 359-362.PubMed
25.
Yonemura Y, Kaji M, Hirono Y, Fushida S, Tsugawa K, Fujimura T, Miyazaki I, Harada S, Yamamoto H: Correlation between overexpression of c-met gene and the progression of gastric cancer. Int J Oncol. 1996, 8: 555-560.PubMed
26.
Zhuang X, Lin S, Zheng J, Wang L, Sun G, Li Y: The prognostic research of expression and relationship between Helicobacter pylori of c-met oncogene correlation with gastric mucosal proliferation. Zhonghua Nei Ke Za Zhi. 2001, 40: 381-384.PubMed
27.
Zhuang X, Zheng J, Lin S, Sun G, Li Y: The prognostic significance of expression of c-met oncogene and its relation to gastric mucosal lesions. Zhonghua Bing Li Xue Za Zhi. 2000, 29: 409-411.PubMed
28.
Huang TJ, Wang JY, Lin SR, Lian ST, Hsieh JS: Overexpression of the c-met protooncogene in human gastric carcinoma–correlation to clinical features. Acta Oncol. 2001, 40: 638-643.CrossRefPubMed
29.
Drebber U, Baldus SE, Nolden B, Grass G, Bollschweiler E, Dienes HP, Holscher AH, Monig SP: The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep. 2008, 19: 1477-1483.PubMed
30.
Lauren P: The two histological main types of gastric carcinoma: diffuse and so-clled intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965, 64: 31-49.PubMed
31.
Mullaney PJ, Wadley MS, Hyde C, Wyatt J, Lawrence G, Hallissey MT, Fielding JW: Mullaney PJ, Wadley MS, Hyde C, Wyatt J, Lawrence G, Hallissey MT, Fielding JW: Appraisal of compliance with the UICC/AJCC staging system in the staging of gastric cancer. Union Internacional Contra la Cancrum/American Joint Committee on Cancer. Br J Surg. 2002, 89: 1405-1408.CrossRefPubMed
32.
Watson NF, Durrant LG, Madjd Z, Ellis IO, Scholefield JH, Spendlove I: Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol Immunother. 2006, 55: 973-980.CrossRefPubMed
33.
Madjd Z, Mehrjerdi AZ, Sharifi AM, Molanaei S, Shahzadi SZ, Asadi-Lari M: CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. Cancer Immun. 2009, 9: 4-PubMedCentralPubMed
34.
McIntire M, Redston M: Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract. Arch Pathol Lab Med. 2012, 136: 496-503.CrossRefPubMed
35.
Mireskandari M, Shafaii AF, Kayser G, Kayser K: Lack of CD117 and rare bcl-2 expression in stomach cancer by immunohistochemistry. An immunohistochemical study with review of the literature. Diagn Pathol. 2006, 1: 7-PubMedCentralCrossRefPubMed
36.
Wei X, Juan ZX, Min FX, Nan C, Hua ZX, Qing FZ, Zheng L: Recombinant immunotoxin anti-c-Met/PE38KDEL inhibits proliferation and promotes apoptosis of gastric cancer cells. J Exp Clin Cancer Res. 2011, 30: 67-PubMedCentralCrossRefPubMed
37.
Migliore C, Giordano S: Molecular cancer therapy: can our expectation be MET?. Eur J Cancer. 2008, 44: 641-651.CrossRefPubMed
38.
Shebl AM, Zalata KR, Amin MM, El-Hawary AK: An inexpensive method of small paraffin tissue microarrays using mechanical pencil tips. Diagn Pathol. 2011, 6: 117-PubMedCentralCrossRefPubMed
39.
Zhao J, Zhang X, Xin Y: Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas. Histol Histopathol. 2011, 26: 1111-1120.PubMed
40.
Tolgay Ocal I, Dolled-Filhart M, D'Aquila TG, Camp RL, Rimm DL: Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer. 2003, 97: 1841-1848.CrossRefPubMed
41.
Heideman DA, Snijders PJ, Bloemena E, Meijer CJ, Offerhaus GJ, Meuwissen SG, Gerritsen WR, Craanen ME: Absence of tpr-met and expression of c-met in human gastric mucosa and carcinoma. J Pathol. 2001, 194: 428-435.CrossRefPubMed
42.
Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E: Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun. 1992, 189: 227-232.CrossRefPubMed
43.
Wu MS, Shun CT, Wang HP, Sheu JC, Lee WJ, Wang TH, Lin JT: Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. Gastroenterology. 1997, 112: 1457-1465.CrossRefPubMed
44.
Tabuenca AD, Aitken DR, Ihde JK, Smith J, Garberoglio C: Factors influencing survival in advanced gastric cancer. Am Surg. 1993, 59: 855-859.PubMed
45.
Monig SP, Zirbes TK, Schroder W, Baldus SE, Lindemann DG, Dienes HP, Holscher AH: Staging of gastric cancer: correlation of lymph node size and metastatic infiltration. AJR Am J Roentgenol. 1999, 173: 365-367.CrossRefPubMed
46.
Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, et al.: Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep. 2011, 25: 1517-1524.PubMed
Metadata
Title
The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays
Authors
Kambiz Sotoudeh
Forough Hashemi
Zahra Madjd
Alireza Sadeghipour
Saadat Molanaei
Elham Kalantary
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2012
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-7-57

Other articles of this Issue 1/2012

Diagnostic Pathology 1/2012 Go to the issue

Case Report

Small duct autoimmune sclerosing cholangitis and Crohn colitis in a 10-year-old child. A case report and review of the literature

Case Report

Prostatic stromal sarcoma with neuroectodermal differentiation

Short report

Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco

Research

Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors

Research

Ezrin overexpression predicts the poor prognosis of gastric adenocarcinoma

Research

Histopathological analysis of vesicular and bullous lesions in Kaposi sarcoma